Mary Crowley Cancer Research (MCCR) announced today the addition of Rodney Olsen to their Board of Directors.
Mary Crowley Cancer Research (MCCR) announced today the addition of Edward Marx to their Board of Directors.
The treatment of advanced prostate cancer has thus traditionally focused on the inhibition of androgen signaling (for example through blockade of the androgen receptor, or inhibition of testosterone production).
The health and safety of the patients at Mary Crowley Cancer Research is always our top priority.
The Be the Difference Foundation presented Runway for Hope, a luncheon and fashion show benefiting Mary Crowley Cancer Research on September 26th.
DALLAS, Texas – Join Be the Difference Foundation for their inaugural luncheon and fashion show, Runway for Hope, benefitting Mary Crowley Cancer Research,
Tempus is a Chicago-based leading technology company that is ushering precision medicine as a means to advance cancer care.
The Board of Mary Crowley Cancer Research is delighted to announce the appointment of Ashley E. Ross, M.D., PhD, as Executive Medical Director.
FDA approves first cancer treatment for any solid tumor with a specific genetic feature
Mary Crowley Cancer Research has opened a new Phase I clinical trial for advanced Type 1 Ewing sarcoma, a rare bone cancer affecting children, adolescents, and young adults.